The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.

Inclusion Criteria:

1. Age is 18 years old or above.
2. Diagnosed as anterior circulation large vessel occlusion stroke by CTA, MRA or DSA.
3. Randomized within 24h after the onset.
4. The NIHSS score is above 5 and the ASPECT score is above 3 points while receiving imaging examination;
5. The mTICI score after endovascular treatment (EVT) is above 2b.
6. informed consent.

Exclusion Criteria:

1. Intracranial hemorrhage confirmed by CT or MRI.
2. mRS score>2 for patients <80 years, or mRS score>1 for those ≥80 years before onset.
3. Pregnant or lactating women.
4. Allergic to contrast agents.
5. Allergic to baricitinib or having contraindications for using baricitinib.
6. Participating in other clinical studies.
7. Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, and unable to be controlled by oral antihypertensive drugs.
8. Genetic or acquired bleeding diathesis, lack of anticoagulant factors or having taken oral anticoagulants and INR >1.7.
9. Hemoglobin value <8g/L.
10. Recent history of using other JAK inhibitors or potent immunosuppressants, including but not limited to the combined use with potent immunosuppressive drugs such as azathioprine, tacrolimus, tofacitinib and fedratinib, etc. Tortuous arteries make the thrombectomy device unable to reach the target blood vessel.
11. Previous history of diagnosed viral hepatitis and tuberculosis.